Effect of Non-invasive Vagus Nerve Stimulation on Cognitive Functions in Diabetic Polyneuropathy Patients

NCT ID: NCT06048653

Last Updated: 2023-09-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-02

Study Completion Date

2024-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Diabetic peripheral neuropathy (DPN) occurs due to long standing hyperglycemia and associated metabolic derangements. Cognitive impairment is a common complication in diabetes mellitus. It is associated with a faster rate of cognitive decline.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This research aims to

* determine the effect of non-invasive Vagus nerve stimulation on cognitive functions in diabetic peripheral neuropathy.
* investigate the correlation between cognitive function and severity of diabetic neuropathy.
* investigate the correlation between cognitive function and quality of life in diabetic peripheral neuropathy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Peripheral Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The control group (GI) will receive a computer based cognitive rehabilitation program (Rehacom system); and the study group (GII) will receive the same program as (GI) in addition to Vagus nerve stimulation.
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

control group

The control group (GI) will receive a computer based cognitive rehabilitation program (Rehacom system)

Group Type EXPERIMENTAL

A computer based cognitive rehabilitation program (Rehacom system)

Intervention Type OTHER

Rehacom cognitive rehabilitation software will be used to treat the cognitive dysfunction

* Patients will receive training for four weeks, two sessions per week.
* Each patient will assume a comfortable sitting position on a chair in front of the screen.
* A report will be generated at the end of the session. It will be used for follow up.
* Session duration will range from 45 to 60 min. including rest period.

study group

The study group (GII) will receive a computer based cognitive rehabilitation program (Rehacom system) in addition to Vagus nerve stimulation.

Group Type EXPERIMENTAL

A computer based cognitive rehabilitation program (Rehacom system)

Intervention Type OTHER

Rehacom cognitive rehabilitation software will be used to treat the cognitive dysfunction

* Patients will receive training for four weeks, two sessions per week.
* Each patient will assume a comfortable sitting position on a chair in front of the screen.
* A report will be generated at the end of the session. It will be used for follow up.
* Session duration will range from 45 to 60 min. including rest period.

Vagus nerve stimulation

Intervention Type DEVICE

stimulation will be applied on cymba conchae of left external ear. A stimulation of frequency of 20 Hz, pulse width of 200 - 300 Ms and intensity of 0.5 mA. The stimulation will be on for 30 s and off for 48 s.The stimulus duration will range from 20 to 40 min.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

A computer based cognitive rehabilitation program (Rehacom system)

Rehacom cognitive rehabilitation software will be used to treat the cognitive dysfunction

* Patients will receive training for four weeks, two sessions per week.
* Each patient will assume a comfortable sitting position on a chair in front of the screen.
* A report will be generated at the end of the session. It will be used for follow up.
* Session duration will range from 45 to 60 min. including rest period.

Intervention Type OTHER

Vagus nerve stimulation

stimulation will be applied on cymba conchae of left external ear. A stimulation of frequency of 20 Hz, pulse width of 200 - 300 Ms and intensity of 0.5 mA. The stimulation will be on for 30 s and off for 48 s.The stimulus duration will range from 20 to 40 min.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with diabetic polyneuropathy
* Female patients.
* age ranges from 40 to 55 years old.
* Duration of diabetic illness started since at least three years.
* Patients with mild to moderate neuropathy according to Toronto clinical neuropathy score
* Patients with cognitive function ranges from 24 - 15 score according to Mini mental state examination
* Patients with HbA1c ranges from seven to nine score.
* Ambulant patients with or without walking aids.
* Medically and psychologically stable patients without cardiac problems, confirmed by Electro Cardiogram (ECG).
* able to understand instructions.

Exclusion Criteria

* Type I diabetes mellitus.
* Severe visual, verbal or acoustic impairments.
* Sever cognitive dysfunctions or that caused by other cause rather than diabetes mellitus.
* Polyneuropathy caused by other cause rather than diabetes mellitus.
* Other neurological problem as stroke.
* Cardiovascular problems.
* Metallic implants
* Illiterate patients.
* Uncooperative patients.
Minimum Eligible Age

40 Years

Maximum Eligible Age

55 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

heba ahmed khalifa

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

heba ahmed khalifa

Ass. Prof. Dr of Physical therapy for Neurology

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Moshera Darwish, Prof. Dr

Role: PRINCIPAL_INVESTIGATOR

Professor of Physical therapy for Neurology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of Physical Therapy

Giza, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

References

Explore related publications, articles, or registry entries linked to this study.

Awad N, Gagnon M, Messier C. The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol. 2004 Nov;26(8):1044-80. doi: 10.1080/13803390490514875.

Reference Type BACKGROUND
PMID: 15590460 (View on PubMed)

Broncel A, Bocian R, Klos-Wojtczak P, Kulbat-Warycha K, Konopacki J. Vagal nerve stimulation as a promising tool in the improvement of cognitive disorders. Brain Res Bull. 2020 Feb;155:37-47. doi: 10.1016/j.brainresbull.2019.11.011. Epub 2019 Nov 29.

Reference Type BACKGROUND
PMID: 31790720 (View on PubMed)

Darwish MH, El-Tamawy MS, Alhirsan SM, El-Anany M, Khalifa HA. Effect of Trans-Auricular Vagal Nerve Stimulation on Cognitive Functions in Diabetic Polyneuropathy Patients. Physiother Res Int. 2025 Apr;30(2):e70063. doi: 10.1002/pri.70063.

Reference Type DERIVED
PMID: 40285458 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P.T.REC/012/003942

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.